×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
IXICO Reports Challenges and Strategic Focus in H1 2024 - TipRanks.com
Tipranks
IXICO plc (GB:IXI) has released an update. IXICO plc, a company specializing in precision analytics for neuroscience, reported a challenging H1 2024 with...
22 hours ago
Is IXICO plc (LON:IXI) Potentially Undervalued?
Yahoo Finance
If you've been keeping tabs on IXI for some time, now may not be the best time to enter into the stock. Its price has risen beyond its industry...
5 months ago
Ixico CEO to step down by end of year
Sharecast.com
Medical imaging analytics company Ixico announced on Friday that its chief executive officer Giulio Cerroni planned to retire from his...
4 months ago
IXICO Full Year 2023 Earnings: Beats Expectations
Simply Wall Street
IXICO ( LON:IXI ) Full Year 2023 Results Key Financial Results Revenue: UK£6.67m (down 23% from FY 2022). Net loss...
5 months ago
IXICO Full Year 2022 Earnings: Beats Expectations
Yahoo News New Zealand
IXICO ( LON:IXI ) Full Year 2022 Results Key Financial Results Revenue: UK£8.64m (down 6.0% from FY 2021). Net income...
6 days ago
IXICO plc Announces Upcoming Financial Update - TipRanks.com
Tipranks
IXICO plc (GB:IXI) has released an update. IXICO plc, a company specializing in neuroscience insights for neurological disease therapies,...
2 weeks ago
Ixico full-year earnings could slightly exceed forecasts
Sharecast.com
Advanced medical imaging analytics specialist Ixico said in an update on Friday that its earnings for the financial year would either meet...
7 months ago
With EPS Growth And More, IXICO (LON:IXI) Is Interesting
Yahoo News UK
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
1 week ago
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Nature
SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab,...
21 months ago
Global Clinical Trial Imaging Market Report 2024-2030 Featuring Key Players Ixico, Navitas Life Sciences, Resonance ...
Yahoo Finance
Global Clinical Trial Imaging Market Global Clinical Trial Imaging Market Dublin, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The "Global Clinical...
5 months ago